3.86 Lenvatinib plus Pembrolizumab or Everolimus for Advanced RCC with Dr. Karine Tawagi

from Plenary Session - inactive due to federal service · host Plenary Session

Today we bring back our popular Journal Club with a Fellow segment. We're joined by Dr. Karine Tawagi of the Oschner Clinic in Louisiana to discuss the CLEAR trial: "Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma" as published in the New England Journal of Medicine. CLEAR: doi.org/10.1056/NEJMoa2035716 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

What this episode covers

NOW PLAYING

0:00 34:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 34 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on May 28, 2021.

What is this episode about?

Can I download this Plenary Session - inactive due to federal service episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!